Dengvaxia

Dengvaxia is a vaccine designed to prevent dengue fever, a mosquito-borne viral infection. This live, attenuated vaccine is administered subcutaneously and is suitable for individuals at risk of dengue exposure.

Dengvaxia is used to protect against dengue fever, a viral infection transmitted by mosquitoes. The vaccine works by stimulating the immune system to produce antibodies against the dengue virus. It is typically recommended for individuals living in or traveling to areas where dengue is endemic.

Common effects of Dengvaxia may include mild to moderate injection site reactions such as pain, redness, or swelling. Some individuals may also experience general symptoms like headache, fatigue, or muscle pain. These effects are usually temporary and resolve on their own.

Dengvaxia should be administered with caution in individuals with a history of severe allergic reactions to any component of the vaccine. It is important to inform healthcare providers about any underlying health conditions or medications before receiving the vaccine. Pregnant women and individuals with weakened immune systems should consult their healthcare provider before vaccination.

Dengvaxia may interact with other vaccines or medications, particularly those that affect the immune system. It is advisable to discuss any current medications or recent vaccinations with a healthcare provider before receiving Dengvaxia. Alcohol consumption does not typically interact with the vaccine, but general health precautions should be followed.